Sept. 22, 2009 (Berlin) — Two new blood tests may offer assistance to form the conclusion of colon and other gastrointestinal cancers less difficult, cheaper, and less repulsive.
The tests, created by Belgian and German researchers, seek for genetic fingerprints of tumor development within the blood. One test may moreover offer assistance to predict whether cancer is likely to spread.
The tests were depicted here at a joint meeting of the European Cancer Organization (ECCO) and the European Society for Restorative Oncology.
ECCO President Alexander Eggermont, MD, head of surgical oncology at the Erasmus University Medical Center in the Netherlands, tells WebMD that the tests may help fill a require for more helpful cancer screening. He was not included with the work.
One in 17 individuals will create colorectal cancer in his or her lifetime. It’s the moment driving cancer killer in the U.S. and Europe.
The chance of biting the dust is reduced significantly in the event that the disease is caught early, when it is most treatable. But numerous people disregard current tests such as colonoscopy and stool test investigation, calling them invasive or just plain terrible, says Joost Louwagie, PhD, of OncoMethylome Sciences in Liege, Belgium, which is developing one of the tests.
Louwagie and colleagues collected blood tests from 193 patients undergoing surgery for colorectal cancer and 688 people who were undergoing colonoscopies.
They looked for two genes, SYNE1 and FOXE1, which have been connected to tumor development.
“We found a high frequency of these qualities in colorectal patients. The same qualities occurred infrequently in noncancerous patients,” Louwagie tells WebMD.
Generally, the test correctly recognized 50% to 60% of cancers, he says. And it accurately recognized more than 90% of individuals with no cancer.
In individuals with early-stage colon cancer, the test performed indeed better, Louwagie says.
“Once approved, the new methylation test might be utilized as a noninvasive screening option for patients who decrease or do not have get to to colonoscopy or do not wish to embrace the fecal occult blood test.”
“The blood sample can be taken by nurses or essential care doctors without the need for extraordinary equipment or preparing, driving to higher rates of persistent compliance,” he says.
The company is talking with a few bigger companies around licensing rights to the test.
The moment test, created by Ulrike Stein, PhD, of the ECRC Charite College of Medicine in Berlin, and colleagues, looks for colon, rectal, and gastric cancers.
The test homes in on a hereditary unique mark, S100A4, that has been linked to the improvement and spread of tumors.
The researchers examined every day blood samples from 185 people with colon cancer, 190 individuals with rectal cancer, 91 gastric cancer patients, and 51 tumor-free volunteers.
“We found that S100A4 was present at essentially higher levels in the group of cancer patients, no matter whether they had colorectal or gastric cancer, than within the tumor-free control bunch,” says Stein.
There were even higher levels in patients who cancer had spread, she says.